Trials / Terminated
TerminatedNCT02964338
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 259 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fremanezumab | Fremanezumab will be administered as per the dose and schedule specified in the respective arms. |
| DRUG | Placebo | Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms. |
Timeline
- Start date
- 2017-01-17
- Primary completion
- 2018-07-18
- Completion
- 2018-07-18
- First posted
- 2016-11-16
- Last updated
- 2021-11-09
- Results posted
- 2019-09-18
Locations
83 sites across 12 countries: United States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02964338. Inclusion in this directory is not an endorsement.